 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...7778798081828384858687...123124» |
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, IO biomarker: Agree subsets of women respond to I/O. Arid1a, MSI high. Maybe Pdl-1 expression and high tmb. But in unselected patients the trials have failed. Javelin 100, javelin 100 parp and imagyn. Pembro/lenvatinib positive in endometrial ca unselected patients and EMPOWER in cervix ca (Twitter) - Aug 14, 2021
- ||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
Clinical, P3 data, Journal: Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. (Pubmed Central) - Aug 14, 2021
P3
Our results show that cabozantinib significantly prolongs progression-free survival and might provide a new treatment option for patients with radioiodine-refractory DTC who have no available standard of care.
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical: A new standard of care lenvatinib and pembrolizumab for first-line metastatic renal cell carcinoma. https://t.co/kSud2AtYf1 (Twitter) - Aug 13, 2021
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, FDA event: ICYMI - @US_FDA approval of #Keytruda-Lenvima combo for advanced renal cell carcinoma "is a significant milestone for newly diagnosed patients...and introduces a promising combination option in the first-line setting,” says our @motzermd (Twitter) - Aug 13, 2021
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, FDA event: FDA approves immunotherapy combo of lenvatinib + pembrolizumab for first-line treatment of patients with advanced #kidneycancer: https://t.co/k8yAxH9wqs Approval based on the CLEAR study, co-led by senior author Dana-Farber's @DrChoueiri: https://t.co/l8oomN5tJ0 via @NEJM (Twitter) - Aug 13, 2021
- | remdesivir / Generic mfg., lenvatinib / Generic mfg.
Preclinical, Journal: Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir. (Pubmed Central) - Aug 13, 2021
Here, we used high-throughput docking to screen 6000 compounds within the DrugBank library for their potential to bind and inhibit the SARS-CoV-2 3 CL main protease, a chymotrypsin-like enzyme that is essential for viral replication...Lenvatinib is a broadly-acting host receptor tyrosine kinase (RTK) inhibitor, but the synergistic effect with remdesivir was not observed with other approved RTK inhibitors (such as pazopanib or sunitinib), suggesting that the mechanism-of-action is independent of host RTKs...Our work shows that combining computational and cellular screening is a means to identify existing drugs with repurposing potential as antiviral compounds. Future studies could be aimed at understanding and optimizing the lenvatinib/remdesivir synergistic mechanism as a therapeutic option.
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Not to be missed at #KCRS21: @DrChoueiri will present the updated results for survival outcomes and tumor response of Lenvantinib + Pembrolizumab from the CLEAR trial! Register now: https://t.co/uhaOhTI7B1 #KCRS21 #AcceleratingCures @OncoAlert (Twitter) - Aug 12, 2021
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical: " ... to continue building on doublets, like pembro/Len with other active drugs, that are able to induce more deep and sustainable remissions." - @DrChoueiri Congrats to everyone! Thank you for your work! #acceleratingcures (Twitter) - Aug 12, 2021
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, FDA event: @US_FDA approves pembrolizumab + lenvatinib combination for first-line treatment of adult patients with advanced #RCC based on results of the phase 3 CLEAR/KEYNOTE-581 Trial. #ReadNow details on UroToday > https://t.co/QI6IssKIsK @Merck @EisaiUS @motzermd @sloan_kettering (Twitter) - Aug 12, 2021
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, FDA event: 🚨🚨RESEARCH NEWS Lenvantinib (@EisaiUS) + Keytruda (@Merck) now @US_FDA approved for #kidneycancer. Wonderful to have this powerful new combo as a treatment option for patients with advanced #RCC. Details: https://t.co/eZJJ1P8CZW @DrChoueiri says ... (Twitter) - Aug 12, 2021
- |||| Keytruda (pembrolizumab) / Merck (MSD)
FDA event: FDA approves frontline pembrolizumab plus lenvatinib for #kidneycancer #FDA #urology #urologist @uroupdate @EisaiUS @Uroweb @OncoAlert #kidneycancer https://t.co/FVd7pdkguI (Twitter) - Aug 12, 2021
- |||||||||| erfonrilimab (KN046) / Alphamab
New P2/3 trial, Metastases: KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent (clinicaltrials.gov) - Aug 11, 2021
P2/3, N=522, Not yet recruiting, Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 11, 2021
P2, N=48, Recruiting, Sponsor: Nanfang Hospital of Southern Medical University
- |||| Keytruda (pembrolizumab) / Merck (MSD)
FDA event: FDA Approves Pembrolizumab Plus Lenvatinib for Frontline Advanced RCC https://t.co/zcPi8yiMNq via @onclive (Twitter) - Aug 11, 2021
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical: @ASCO @US_FDA Alert👉Today Lenvatinib + Pembrolizumab combo was approved for 1st line treatment of patients with metastatic/advanced RCC @kidneycancer Weblink: https://t.co/wAHHpgLWb2 based on the data in @NEJM 👇: https://t.co/7QyHWl33H1 @motzermd @DrChoueiri Great news!! (Twitter) - Aug 11, 2021
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
FDA event: Lenvatinib/Pembrolizumab is approved by the FDA for 1st line renal cancer. The significant OS signal (HR.66) is similar to other combos, but the RR (74%) and PFS (HR .39) is compelling. My opinion remains ‘pick one and use it well’, with no reason not to use Len/Pem if you want (Twitter) - Aug 11, 2021
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, FDA event: Another highly effective therapy for #kidneycancer gets available: @US_FDA approved the combination of lenvatinib + pembrolizumab for first-line treatment of patients with advanced renal cell carcinoma. (Twitter) - Aug 11, 2021
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical: Another effective first line option for patients with metastatic #kidneycancer!! Lenvatinib and pembrolizumab is approved. @KidneyCancer @kcCURE @kidneycan (Twitter) - Aug 11, 2021
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, FDA event: Just in: @US_FDA approved the combination of lenvatinib + pembrolizumab for first-line treatment of patients with advanced renal cell carcinoma (RCC). Approval based on CLEAR study published @NEJM @ASCO @OncoAlert https://t.co/3Rfj1YDVKV (Twitter) - Aug 11, 2021
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, FDA event: Exciting to see FDA approval for lenvatinib + pembrolizumab for advanced clear cell RCC based in on CLEAR data! More frontline options for patients. Need strategies to optimize therapy selection in front line space. (Twitter) - Aug 11, 2021
- | entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma, Nexavar (sorafenib) / Bayer, Amgen
Journal, PD(L)-1 Biomarker, IO biomarker: The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells. (Pubmed Central) - Aug 11, 2021
P1
Knock down of HDACs1/2/3 prevented the lenvatinib and entinostat combination from regulating PD-L1 and MHCA expression. Collectively, our data demonstrate that lenvatinib and entinostat interact to kill liver cancer cells via ROS-dependent activation of ATM and inactivation of eIF2α, resulting in greater levels of toxic autophagosome formation and reduced expression of protective mitochondrial proteins.
- |||||||||| Loqtorzi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci
New P3 trial, Tumor mutational burden, IO biomarker, Metastases: A clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC) (EUDRACT) - Aug 10, 2021
P3, N=519, Ongoing, Sponsor: Shanghai Junshi Biosciences Co., Ltd`Shanghai Junshi Biosciences Co., Ltd.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial, Metastases: The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 9, 2021
P1/2, N=142, Enrolling by invitation, Sponsor: Xinrui Zhu
- lenvatinib / Generic mfg.
[VIRTUAL] Transcatheter Arterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable HCC (TACTICS-L) in Japan: Interim analysis (ROOM 2) - Aug 7, 2021 - Abstract #APPLE2021APPLE_138;
- || Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer. (Pubmed Central) - Aug 7, 2021
Some tissue and circulating biomarkers have been investigated, those involved in the angiogenic pathways being the most promising. Finally, prospective clinical trials aimed at evaluating predictive markers for therapeutic response are needed for tailoring patient management and allowing more appropriate treatment choices.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial: Avelumab + lenvatinib for children with primary CNS tumors (EUDRACT) - Aug 7, 2021
P1/2, N=18, Ongoing, Sponsor: Merck Healthcare KGaA
- Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON () - Aug 6, 2021 - Abstract #ILCA2021ILCA_100;
P=N/A, P3
Despite differing timelines and study design, baseline characteristics were similar between patients enrolled in these studies. Median OS for this extended patient population, including patient subgroups who were excluded from IMbrave150, was similar to the phase 3 SHARP study (10.7 months).
- Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Systematic review and meta-analysis of RCT (2002-2020): is etiology relevant for immunotherapies? () - Aug 6, 2021 - Abstract #ILCA2021ILCA_95;
Among 49 high-quality RCTs conducted in HCC during 2002-2020, nine resulted in positive results. A meta-analysis of systemic therapies suggest that immunotherapies are more effective in viral vs non-viral etiologies
- Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma () - Aug 6, 2021 - Abstract #ILCA2021ILCA_70;
We identified an 11-gene signature of response to anti-PD1 therapy in first line advanced HCC, which was validated in other solid tumors. This signature did not identify responders after TKI treatment, thus calling for the need of biopsies prior to anti-PD1 therapy to enable biomarker-based precision oncology.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal, Real-world evidence: Multikinase inhibitors for the treatment of radioiodine refractory thyroid cancer: what have we learned from the 'real-world' experience? (Pubmed Central) - Aug 6, 2021
RWD analysis has corroborated RCT results in terms of MKI efficacy for both first-line and salvage treatment in patients with RAIR-DTC. The safety profiles emerging from RWDs seem to justify the caution recommended by most scientific guidelines.
- | Opdivo (nivolumab) / Ono Pharma, BMS
Journal, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Immunotherapy combinations in advanced nonsmall cell lung cancer. (Pubmed Central) - Aug 6, 2021
Platinum-based doublets combined with an immune checkpoint inhibitor have become standard first-line therapy. Other combinations are under clinical development.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis (Veronese 2501) - Aug 5, 2021 - Abstract #AUA2021AUA_2499;
Conversely, lenvatinib plus pembrolizumab may provide the most favorable PFS and ORRs, while nivolumab plus ipilimumab the lowest toxicity. However, important population differences may potentially undermine the generalizability and the robustness of these findings.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Salvage immune checkpoint inhibitor (IO) plus tyrosine kinase inhibitor (TKI) combination therapy for metastatic renal cell carcinoma (mRCC). (Bellini 2004) - Aug 5, 2021 - Abstract #AUA2021AUA_1650;
IO/TKI combination therapy is effective and safe beyond the 1L setting, although prior tx history impacts outcomes considerably. These observations will need to be confirmed in prospective studies.
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab/Lenvatinib Under Evaluation in Frontline Non–Clear Cell RCC @ChungHanLee3 @sloan_kettering @ASCO #ASCO21 #kcsm https://t.co/NovoByBimM (Twitter) - Aug 4, 2021
- || lenvatinib / Generic mfg.
Clinical, Journal: Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. (Pubmed Central) - Aug 4, 2021
These observations will need to be confirmed in prospective studies. PLR predicted overall survival in patients with unresectable HCC who received lenvatinib.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: 475-0708-MT-Lung: Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC (clinicaltrials.gov) - Aug 3, 2021
P2, N=46, Not yet recruiting, Sponsor: Dr Joanne CHIU
- |||| GI-101 / GI Innovation
Enrollment open, Metastases: KEYNOTE-B59: GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors (clinicaltrials.gov) - Aug 3, 2021
P1/2, N=374, Recruiting, Sponsor: GI Innovation, Inc.
PLR predicted overall survival in patients with unresectable HCC who received lenvatinib. Not yet recruiting --> Recruiting
- AiTan (rivoceranib) / HLB Bio Group, Balversa (erdafitinib) / J&J, Otsuka
[VIRTUAL] Cell-free circulating tumor DNA in patients with Recurrent Adenoid Cystic Carcinoma and the potential activity of selective fibroblast growth factor receptor (FGFR) inhibitors () - Aug 3, 2021 - Abstract #AHNS2021AHNS_979;
ctDNA is now widely available and should be included in the evaluation of patients with recurrent and metastatic ACC. FGFR genomic abnormalities can be a driver mutation in patients with refractory advanced ACC and the activity of Erdafinib should be evaluated in this subset of patients with few therapeutic options.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Genetic Testing, Treatment Patterns, and Clinical Outcomes Among Patients With Advanced/Metastatic Medullary Thyroid Cancer in the United States: A Retrospective Medical Record Review Study () - Aug 3, 2021 - Abstract #AHNS2021AHNS_655;
For the treatment of advanced/metastatic MTC, no specific preference of sequencing systemic agents was observed in the first- and second-line settings. The estimated OS is consistent with that observed from Surveillance, Epidemiology, and End Results database for patients with de novo metastatic MTC.
- | lenvatinib / Generic mfg.
Journal: EGFR Inhibitors Synergize with Lenvatinib for Liver Cancer Treatment. (Pubmed Central) - Aug 1, 2021
The estimated OS is consistent with that observed from Surveillance, Epidemiology, and End Results database for patients with de novo metastatic MTC. EGFR inhibition and lenvatinib exhibit synthetic lethality in hepatocellular carcinoma.
- | lenvatinib / Generic mfg.
Preclinical, Journal: Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. (Pubmed Central) - Jul 31, 2021
Additionally, PDX models reflected the heterogeneous sensitivity to lenvatinib treatment and CDH1 might be vital to lenvatinib-resistance. PDX models provide a powerful platform for preclinical drug discovery, and potentially facilitate the implementation of personalized medicine and improvement of survival of ICC cancer patient.
- lenvatinib / Generic mfg.
Lenvatinib candidate patient What have we learned? () - Jul 31, 2021 - Abstract #AEEH2021AEEH_123;
PDX models provide a powerful platform for preclinical drug discovery, and potentially facilitate the implementation of personalized medicine and improvement of survival of ICC cancer patient. Sponsored by EISAI-MSD
- || Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: Updates on the Diagnosis and Management of Hepatocellular Carcinoma. (Pubmed Central) - Jul 29, 2021
For advanced disease, sorafenib used to be the only option until a couple of years ago...Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepato-Gastroenterol 2021;11(1):32-40.
- || Keytruda (pembrolizumab) / Merck (MSD)
Thanks so much. Lenvatinib pembro combo? (Twitter) - Jul 29, 2021
- ||| everolimus / Generic mfg., lenvatinib / Generic mfg.
Clinical: Consider lenvatinib/everolimus if feasible. Any genomic data? Best wishes to the patient. (Twitter) - Jul 29, 2021
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB VS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: STUDY 309/KEYNOTE-775 (Hall 1) - Jul 29, 2021 - Abstract #IGCS2021IGCS_111;
Conclusions LEN + pembro demonstrated statistically significant and clinically meaningful improvements in PFS, OS, and ORR vs TPC both in pts with aEC that was pMMR and in pts with aEC irrespective of MMR status. The safety profile of LEN + pembro was manageable and consistent with previously reported studies.
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] RANDOMIZED PHASE 3 STUDY OF LENVATINIB PLUS PEMBROLIZUMAB FOR ADVANCED ENDOMETRIAL CANCER (AEC): SUBGROUP ANALYSIS OF PATIENTS WITH DNA MISMATCH REPAIR DEFICIENT (DMMR) TUMORS (Hall 1) - Jul 29, 2021 - Abstract #IGCS2021IGCS_68;
Patients in Study 309/KEYNOTE-775 were randomized 1:1 to lenvatinib 20 mg orally daily + pembrolizumab 200 mg IV Q3W or TPC (doxorubicin 60 mg/m2 IV Q3W or paclitaxel 80 mg/m2 IV QW [3 weeks on/1 week off]). LEN+pembro improved PFS, OS, and ORR vs TPC in patients with dMMR aEC, with a manageable safety profile generally consistent with all-comers and previous studies.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical data, Retrospective data, Journal: Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. (Pubmed Central) - Jul 28, 2021
TKI-IO combinations, particularly N+P and N+C, are well tolerated and efficacious. Although further prospective research is essential, slow disease progression on IO or TKI monotherapy may be safely controlled with addition of either TKI or IO.
- || adavosertib (AZD1775) / AstraZeneca, Nexavar (sorafenib) / Bayer, Amgen
Biomarker, Clinical, Journal: Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer. (Pubmed Central) - Jul 28, 2021
Furthermore, combination of adavosertib with lenvatinib was more effective than either agent alone in a xenograft model of follicular thyroid cancer. These results show that adavosertib has the potential in treating DTC.